| Original language | English |
|---|---|
| Pages (from-to) | 1149-1151.e3 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 03-2020 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, No. 3, 03.2020, p. 1149-1151.e3.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Long-term dynamics of omega-5 gliadin-specific IgE levels in patients with adult-onset wheat allergy
AU - Hamada, Yuto
AU - Chinuki, Yuko
AU - Fukutomi, Yuma
AU - Nakatani, Eiji
AU - Yagami, Akiko
AU - Matsunaga, Kayoko
AU - Oda, Yoshiko
AU - Fukunaga, Atsushi
AU - Adachi, Atsuko
AU - Hiragun, Makiko
AU - Hide, Michihiro
AU - Morita, Eishin
N1 - Funding Information: This study was supported by a grant from the Japan Agency for Medical Research and Development (grant no. 17ek0410020h0003).Conflict of interests: Y. Chinuki, Y. Fukutomi, M. Hide, and E. Morita report grants from the Japan Agency for Medical Research and Development, during the conduct of the study. Y. Chinuki reports personal fees from Kaken, Kyouwa Hakko Kirin Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Novartis Pharma K.K., MSD K.K., TAIHO Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Santen Pharmaceutical Co., Ltd, and Torii Pharmaceutical Co., Ltd, outside the submitted work. Y. Fukutomi reports personal fees from Thermo Fisher Diagnostics K.K., Torii Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Novartis Pharma K.K., MSD K.K., and TAIHO Pharmaceutical Co., Ltd, outside the submitted work. E. Nakatani reports personal fees from Celgene K.K., outside the submitted work. A. Fukunaga reports personal fees from Kaken, Kyorin Pharmaceutical Co., Ltd, Sanofi K.K., TAIHO Pharmaceutical Co., Ltd, Shire Plc, Sumitomo Dainippon Phrma Co., Ltd, Torii Pharmaceutical Co., Ltd, Maruho Co., Ltd, and CSL Bering K.K.; grants and personal fees from Novartis Pharma K.K., and Mitsubishi Tanabe Pharma Corporation, outside the submitted work. M. Hide reports personal fees from Kaken, Kyorin Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Sysmex Corporation, and Teikoku Seiyaku Co., Ltd; grants and personal fees from Kyouwa Hakko Kirin Co., Ltd, Novartis Pharma K.K., MSD K.K., TAIHO Pharmaceutical Co. Ltd, SHIONOGI & Co., Ltd, Torii Pharmaceutical Co., Ltd, and Sanofi K.K., outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2020/3
Y1 - 2020/3
UR - https://www.scopus.com/pages/publications/85075396161
UR - https://www.scopus.com/pages/publications/85075396161#tab=citedBy
U2 - 10.1016/j.jaip.2019.10.008
DO - 10.1016/j.jaip.2019.10.008
M3 - Article
C2 - 31678299
AN - SCOPUS:85075396161
SN - 2213-2198
VL - 8
SP - 1149-1151.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -